Explore 3 Stock Ideas & Industry Insights Download Free Report

General News

Why Are Cybersecurity Stocks Moving on AI Headlines, and What Are Investors Missing After the October 22 PHP Flaw Rally?

Cybersecurity shares did not sell off as a group on Thursday, October 22. Palo Alto Networks (NASDAQ:PANW) rose 2.21% to close at $354.92 and Zscaler (NASDAQ:ZS) rose 2.78% to $237.76, while CrowdStrike (NASDAQ:CRWD) fell 0.58% to $237.94 and Fortinet (NASDAQ:FTNT) fell 0.61% to $172.98. …

Vinay Lochav | 23 October 2026

What Moved After the Bell: RingCentral, Robert Half, Deckers and Western Digital

● Robert Half jumped to $42.00 after staffing revenue grew for the first time since 2022.

Nitish Kishor | 23 October 2026

Why a Strategist Sees 'Some Holes in the AI Story' as the Selloff Stays Confined to Tech

● The Nasdaq Composite fell 694 points to 26,008.86, losing about $1 trillion in market value.

Nitish Kishor | 23 October 2026

Why the AI Power Trade Suddenly Lost Its Spark

● MasTec, Dycom and Primoris hit 52-week lows.

Nitish Kishor | 23 October 2026

How Airlines Are Grappling With Soaring Fuel Costs

● Southwest reported record revenue per available seat mile and earnings of $0.66 a share.

Nitish Kishor | 23 October 2026

How the Great Rotation Out of AI Played Out in One Session

● About two of every three S&P 500 stocks rose despite the Nasdaq's 694-point drop.

Nitish Kishor | 23 October 2026

How Asian Markets Tumbled Before Wall Street Opened

● China's CSI 300 closed at 4,036.30, more than a fifth below its June 22 peak.

Nitish Kishor | 23 October 2026

What a Weekly Investor Survey Says: Bears Outnumber Bulls

● The VIX jumped 2.35 points to 19.03 on Thursday.

Nitish Kishor | 23 October 2026

What Microsoft, Alphabet and Amazon Must Show When They Report Next Week

● Meta posted record revenue of $64.6 billion, yet shares had their worst day since July.

Nitish Kishor | 23 October 2026

Why Biotech Traders Were Glued to FDA Decisions on Thursday

● Biohaven soared to around $14.55 after the FDA accepted its resubmitted rare disease drug application.

Nitish Kishor | 23 October 2026
Support

Hi! How can we help you today?

Loading…